BioCryst Pharmaceuticals, Inc Earning Date (BCRX)

USA |NASDAQ |USD

BCRX Earnings Date

|
Report Date Period Ending EPS Forecast Last Quarter's EPS Last Year's EPS
Aug 3, 2022 Jun 2022 - - $-0.24
Report Date Period Ending Revenue Forecast Last Quarter’s Revenue Last Year’s Revenue
Aug 3, 2022 Jun 2022 - - $49.96M

Biocryst Pharmaceuticals, Inc's next earnings date is Wednesday, Aug 3, 2022 for the fiscal quarter ending Jun 2022.

BCRX Earnings Date & History Chart

BCRX Earnings & Revenue Forecast

BCRX Earnings Forecast

|
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2022 13 $-0.95 $-1.42 $-0.48

BCRX Earnings Revision Trend

|
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2022 6 / 0 $-0.99 $-1.00 $-0.98

BCRX Revenue Forecast

|
Period End # of Analysts Revenue Forecast Low Revenue Forecast High Revenue Forecast
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2022 13 $249.24M $161.00M $317.80M

BCRX Earnings Date & Revenue History

BCRX Earnings History

|
Show More
Show More

BCRX Revenue History

|
Show More
Show More

Biocryst Pharmaceuticals, Inc Next Earnings Date & Report

BCRX Next Earnings Date & Report Preview: Jun 2022 (FQ)

BCRX's next earnings date is Wednesday, Aug 3, 2022 for the fiscal quarter ending Jun 30, 2022.

Biocryst Pharmaceuticals, Inc Previous Earnings Dates & Reports

BCRX Previous Earnings Date & Report Recap: Mar 2022 (FQ)

Biocryst Pharmaceuticals, Inc's previous earnings date was May 5, 2022 for its fiscal quarter ended Mar 31, 2022.

BCRX Previous Earnings Date & Report Recap: Dec 2021 (FY)

Biocryst Pharmaceuticals, Inc's previous annual earnings date was Jan 10, 2022 for its fiscal year ended Dec 31, 2021.

BCRX's earnings per share (EPS) was $-1.03, beating the consensus analysts forecast of $-1.21 by -14.88% , and higher than the previous year's EPS (Dec 2020) by -4.63%.

Revenues were $157.17M, worse than the forecast of $159.45M by -1.43%, and up by 782.38% from previous year's revenue.

The company reported a net income of $-184.06M.

Biocryst Pharmaceuticals, Inc reported a free cash flow of $-144.54M for its fiscal year, compared to $-137.73M a year ago.

The company ended the fiscal year with $593.24M in total debt, an increase of 115.23% compared to the previous year.